Bitesize education

Explore expert insights and educational material on CAR T-cell therapy and access up-to-date information on NHL. The Kite Medical Hub is a non-promotional website intended for healthcare professionals in the UK and Ireland, designed, built and funded by Kite, a Gilead Company.

October 2020

eRMM Tool

Welcome to eRMM Tool an interactive training tool on the management of cytokine release syndrome and neurotoxicity in your YESCARTA® (axicabtagene ciloleucel) CAR T patients.

A CAR T patient avatar will take you on their treatment journey: from preparing your delivery centre, handling and administering treatment to managing any side effects promptly.

Upon completing a quiz at the end, you will be awarded an accredited CPD Certificate.


October 2020

Additional monitoring required.

Adverse events should be reported. For the UK, reporting forms and information can be found at via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Gilead at or +44 (0) 1223 897500.
Adverse events should be reported. For Ireland, reporting forms and information can be found at and can be reported to HPRA on +353 1 6764971. Adverse events should also be reported to Gilead at or +44 (0) 1223 897500.

Latest podcast

See more podcasts
29 Jul 2021
(DURATION: 24:38 - 23 MB)

Autologous stem cell transplantation: Selecting patients and managing risk

Dr Keith Wilson, Consultant Haematologist at Cardiff and Vale University Health Board, discusses how patients with diffuse large B-cell lymphoma are selected for autologous stem cell transplantation and how they are managed thereafter, including the importance of considering CAR T as a 3rd-line therapy at an early stage.

December 2021

Latest events

See more events
06 Oct 2021

GIO-Med hybrid event 2021

Explore highlights from the 2021 Gilead Immuno-Oncology Medical Education (GIO-Med) hybrid event, first broadcast as a live event, and now available as a series of on-demand videos.

View event

CAR T, chimeric antigen receptor T-cell; GIO-Med, Gilead Immuno-Oncology Medical Education; NHL, non-Hodgkin lymphoma; UK, United Kingdom.